Abstract
BACKGROUND: Epidermal growth factor receptor (EGFR) gene mutations can lead to distant metastasis in non-small cell lung cancer (NSCLC). When the primary NSCLC lesions are removed or cannot be sampled, the EGFR status of the metastatic lesions are the potential alternative method to reflect EGFR mutations in the primary NSCLC lesions. This review aimed to evaluate the potential of magnetic resonance imaging (MRI) radiomics based on extrapulmonary metastases in predicting EGFR mutations through a systematic reviews and meta-analysis. MATERIALS AND METHODS: A systematic review of the studies on MRI radiomics based on extrapulmonary metastases in predicting EGFR mutations. The area under the curve (AUC), sensitivity (SNEC), and specificity (SPEC) of each study were separately extracted for comprehensive evaluation of MRI radiomics in predicting EGFR mutations in primary or metastatic NSCLC. RESULTS: Thirteen studies were ultimately included, with 2369 cases of metastatic NSCLC, including five studies predicting EGFR mutations in primary NSCLC, eight studies predicting EGFR mutations in metastatic NSCL. In terms of EGFR mutations in the primary lesion of NSCLC, the pooled AUC was 0.90, with SENC and SPEC of 0.80 and 0.85, respectively, which seems superior to the radiomics meta-analysis based on NSCLC primary lesions. In terms of EGFR mutations in NSCLC metastases, the pooled AUC was 0.86, with SENC and SEPC of 0.79 and 0.79, respectively, indicating moderate evaluation performance. CONCLUSIONS: MRI radiomics helps to predict the EGFR mutation status in the primary or metastatic lesions of NSCLC, serve as a high-precision supplement to current molecular detection methods.